Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

AST-487

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Novartis

Drug class:

RET inhibitor, FLT3 inhibitor

Related drugs:

‹

flonoltinib (0)

lenvatinib (90)

selpercatinib (67)

pralsetinib (49)

TAS0953/HM06 (7)

JNJ-26483327 (0)

quizartinib (40)

ripretinib (11)

pexidartinib (6)

flonoltinib (0)

›

RET mutation	Thyroid Gland Carcinoma	RET mutation	Thyroid Gland Carcinoma	CB-228 + AST-487 Sensitive: D – Preclinical CB-228 + AST-487 Sensitive : D	CB-228 + AST-487 Sensitive: D – Preclinical CB-228 + AST-487 Sensitive : D
RET mutation	Thyroid Gland Carcinoma	RET mutation	Thyroid Gland Carcinoma	AST-487 Sensitive: D – Preclinical AST-487 Sensitive : D	AST-487 Sensitive: D – Preclinical AST-487 Sensitive : D
RET mutation	Melanoma	RET mutation	Melanoma	AST-487 Sensitive: D – Preclinical AST-487 Sensitive : D	AST-487 Sensitive: D – Preclinical AST-487 Sensitive : D
TERT mutation	Solid Tumor	TERT mutation	Solid Tumor	AST-487 Sensitive: D – Preclinical AST-487 Sensitive : D	AST-487 Sensitive: D – Preclinical AST-487 Sensitive : D
TERT overexpression	Solid Tumor	TERT overexpression	Solid Tumor	AST-487 Sensitive: D – Preclinical AST-487 Sensitive : D	AST-487 Sensitive: D – Preclinical AST-487 Sensitive : D